Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2377–2400 of 7,258 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: High-Risk Clear all

Conditions: Metabolic Syndrome X
Interventions: LY518674; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma, Metastatic Mucosal Melanoma, Metastatic Non-Cutaneous Melanoma, Non-Cutaneous Melanoma, Recurrent Cutaneous Melanoma, Recurrent Mucosal Melanoma, Recurrent Non-Cutaneous Melanoma
Interventions: Biospecimen Collection, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Pembrolizumab, Positron Emission Tomography, Quality-of-Life Assessment, Recombinant Interferon Alfa-2b; Procedure · Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 1,301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 552
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 379 more

Conditions: Splenomegaly, Myelofibrosis
Interventions: Ruxolitinib, Allogeneic Stem Cell Transplantation, Levetiracetam, Eltrombopag, Busulfan, Romiplostim, Fludarabine phosphate, Cyclophosphamide, Mesna, Tacrolimus; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prostate Cancer
Interventions: Radiation Therapy followed by prostatectomy; Radiation
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: Up to 69 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Ovarian Neoplasms, Ovary Cancer, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, High Grade Serous Carcinoma, Peritoneal Carcinoma, Peritoneal Neoplasms, Adnexal Mass, Ovarian Diseases
Interventions: Hysteroscopic cell sampling of the fallopian tube; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 10
States / cities: San Diego, California • San Francisco, California • Jacksonville, Florida + 7 more

Conditions: Heart Failure, Physical Activity
Interventions: High intensity exercise, Moderate intensity exercise; Other
Lead sponsor: Georgia State University; Other
Eligibility: 40 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Adverse Drug Event
Interventions: Audit and feedback - letter and report; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: Not listed
Enrollment: 11,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Adenocarcinoma of the Prostate
Interventions: high dose-rate brachytherapy, intensity-modulated radiation therapy; Procedure
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: Male only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2012
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Facet Syndrome of Lumbar Spine
Interventions: Non-Invasive Thermal Ablation of the Medial Branch Nerves (Neurolyser XR), Sham procedure; Device · Other
Lead sponsor: FUSMobile Inc.; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 10
States / cities: Stamford, Connecticut • Jacksonville, Florida • Miami, Florida + 6 more

Conditions: High-Intensity Interval Training, Resistance Training
Interventions: High-velocity interval training, Resistance training; Other
Lead sponsor: University of Miami; Other
Eligibility: 55 Years to 90 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Coral Gables, Florida

Conditions: High-grade Extra Pulmonary Neuroendocrine Cancer
Interventions: All patients- TAS-102; Drug
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hypertension
Interventions: Low sodium diet, high sodium diet; Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 30 Years to 65 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Acute Myeloid Leukemia, Blasts More Than 10 Percent of Bone Marrow Nucleated Cells, High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome
Interventions: Liposome-encapsulated Daunorubicin-Cytarabine, Quizartinib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Coronary Arterial Disease (CAD), Percutaneous Coronary Intervention (PCI)
Interventions: Prasugrel, Clopidogrel; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Colorectal Cancer
Interventions: irinotecan hydrochloride, surgical procedure; Drug · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2001
U.S. locations: 1
States / cities: New York, New York

Conditions: Non Small Cell Lung Cancer
Interventions: Pegilodecakin, Pembrolizumab; Biological · Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 74
States / cities: Huntsville, Alabama • Tempe, Arizona • Beverly Hills, California + 66 more

Conditions: Multiple Myeloma
Interventions: High-Dose Density Therapy; Procedure
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Traumatic Stress Disorder, Post Traumatic Stress Disorder, Trauma and Stressor Related Disorders, Mental Disorders, Exercise
Interventions: High Intensity Interval Training (HIIT), Waitlist; Behavioral · Other
Lead sponsor: University of Georgia; Other
Eligibility: 18 Years to 39 Years · Female only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Athens, Georgia

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: Cyclophosphamide/Glatiramer acetate; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
Interventions: OLAPARIB; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Female only
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 35
States / cities: Anchorage, Alaska • La Jolla, California • Los Angeles, California + 29 more

Conditions: Sarcoma
Interventions: recombinant interferon alfa, thalidomide, adjuvant therapy; Biological · Drug · Procedure
Lead sponsor: Herbert Irving Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: New York, New York

Conditions: Lung Cancer
Interventions: filgrastim, carboplatin, etoposide, ifosfamide, paclitaxel, peripheral blood stem cell transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Herbert Irving Comprehensive Cancer Center; Other
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 1
States / cities: New York, New York

Conditions: Hypercholesterolaemia
Interventions: Alirocumab, Placebo, Lipid-Modifying Therapy (LMT), Antihyperglycemic Drug; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 517 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 29
States / cities: Encino, California • Fresno, California • Oakland, California + 25 more

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Interventions: DC-Ova, DC Ova with Cyclophosphamide; Biological
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older · Female only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

A Mechanistic Study of the Effects of LY518674 on High-Density Lipoprotein Cholesterol (HDL-C) Metabolism

Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly

Radiation Therapy Followed by Surgery in High-Risk, Localized Carcinoma of the Prostate

Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy

High Intensity Interval Training in Heart Failure

Improving Wisely - Polypharmacy

High Dose-Rate Brachytherapy and/or Intensity Modulated External Beam Radiation Therapy for Prostate Cancer

Double Arm Pivotal Study to Evaluate the Neurolyser XR for the Treatment of Chronic Low Back Pain

Speed-specific Training and Ultrasound

TAS-102 in Extrapulmonary Neuroendocrine Carcinoma

Renal Metabolism in Salt-sensitive Human Blood Pressure

Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome

Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding and Ischemic Risk Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study (TAILOR-BLEED-2)

Irinotecan in Treating Patients With Metastatic Colorectal Cancer

Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer

UARK 2003-41: A Study of High-Dose Density Therapy in Patients With Multiple Myeloma

Effects of a Short-term Exercise Intervention on Sleep in Women Exposed to Trauma: A Randomized Controlled Trial

High Dose Cyclophosphamide Followed by Glatiramer Acetate in the Treatment of Relapsing Remitting Multiple Sclerosis

Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status

Interferon Alfa and Thalidomide in Treating Patients With Soft Tissue Sarcoma or Bone Sarcoma

High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Lung Cancer

Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)

Dendritic Cell Vaccine for High Risk Ovarian Cancer Patients